{
  "slug": "cota-healthcare",
  "name": "Cota Healthcare",
  "description": "Cota Healthcare is a healthcare technology company that uses its proprietary Cota Nodal Address (CNA) system to extract, organize, and analyze real-world data from electronic health records. This provides precision medicine insights, improves cancer care, and accelerates oncology research and drug development.",
  "url": "https://optimly.ai/brand/cota-healthcare",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://cota-healthcare.com",
  "baiScore": 38,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Challenger",
  "archetype_status": "active",
  "category": "Healthcare",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-26T00:03:24.812Z",
  "verifiedVitals": {
    "website": "cotahealthcare.com",
    "founded": "2011",
    "headquarters": "Boston, MA",
    "pricing_model": "Likely a multi-tiered subscription-based model for platform access and data licenses, complemented by project-based fees for custom analytics, consulting services, and research collaborations.",
    "core_products": "Cota Nodal Address (CNA) technology, Cota Evidence (Real-World Evidence platform), Cota Oncology Insights, Cota Life Sciences Solutions, Cota for Providers.",
    "key_differentiator": "Its proprietary Cota Nodal Address (CNA) system, which offers a unique, clinically validated methodology for structuring and standardizing complex, unstructured real-world oncology data at a granular level, enabling highly precise insights beyond what generic data analytics platforms can achieve.",
    "target_markets": "Oncology providers (hospitals, health systems, clinics), pharmaceutical companies, life sciences organizations, academic research institutions, clinical research organizations (CROs).",
    "employee_count": "100-250",
    "funding_stage": "Growth Stage (Series C funding announced in 2021)",
    "subcategory": "Real-World Evidence (RWE)"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Clinical Trial & Manual Chart Review: Relying solely on prospective, randomized controlled trials for evidence, combined with manual abstraction and analysis of patient charts, which is hi",
      "Healthcare Data Consulting Firms: Engaging specialized consulting firms to perform bespoke data aggregation and analysis, often lacking the standardized, scalable, and automated data structuring capab",
      "Continue with Fragmented Data Utilization: Maintaining current practices of fragmented data management, leading to missed opportunities for personalized cancer treatment, slower drug development cycle"
    ],
    "solutionIntents": [
      "Cota Healthcare real world evidence",
      "Cota Nodal Address technology",
      "oncology data analytics solutions",
      "Cota Healthcare competitors",
      "Generic EHR Data Analytics Tools: Utilizing general-purpose electronic health record (EHR) analytics software that can extract basic structured data but lacks the specialized, clinically validated met"
    ],
    "evaluationIntents": [
      "Cota Healthcare pricing model"
    ]
  },
  "timestamp": 1785296584509
}